SCHEMBL2482209

SCHEMBL2482209

CC(C)(C)OC(=O)N1CCC(Nc2ccc(Nc3cc(NCc4ccccc4)c(C(N)=O)cn3)cc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 11/20 0.63
IRAK4 Q9NWZ3 5/20 0.59
JAK2 O60674 3/20 0.59
JAK1 P23458 2/20 0.59
TYK2 P29597 2/20 0.59
CSF1R P07333 1/20 0.48
BTK Q06187 1/20 0.48
ACHE P22303 1/20 0.48
ALDH1A1 P00352 2/20 0.48
CCNT1 O60563 1/20 0.48
NPC1 O15118 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SYK P43405 1/20 0.47
LMNA P02545 1/20 0.44
BRD4 O60885 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2483610 0.90 JAK3 (0.58) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL13337945 0.87 JAK3 (0.81) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2481708 0.85 JAK3 (0.64) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2485194 0.85 JAK3 (0.64) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12321575 0.84 JAK3 (0.47) JAK3IRAK4JAK2JAK1ALDH1A1
SCHEMBL2483165 0.83 JAK3 (0.54) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2695821 0.82 JAK3 (0.62) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12322664 0.82 JAK3 (0.47) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2480978 0.82 JAK3 (0.56) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2480980 0.82 JAK3 (0.56) JAK3IRAK4JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102227409-B Pyridine-3-carboxyamide derivative KOWA CO 2014-03-26 CN disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA JAK3 1/4885IRAK4 128/4885JAK2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.